Path Forward: October 2026
The first Path Forward issue establishes the baseline. There is no prior issue to compare against. This October issue records the archive's opening position so later scans can report genuine changes rather than repeat the landscape.
Where the evidence points now
The October baseline ranks ten directions, records four human-signal trials, separates biological revival from informational preservation, and names five evidence rules. No intervention has extended human lifespan. The archive's opening position is a map of where credible evidence could first appear, not a claim that it has.
Follow convergence, not spectacle.
The next credible turn will not be one dramatic headline. It will be independent replication, validated measurement, targeted delivery, and function that lasts.
Functional healthspan evidence, led by mTOR, senolytics, and MSC programs.
Partial reprogramming has the strongest mouse effect sizes but lacks human safety data.
Watch closely
- Human mTOR trials with clinical endpoints rather than clock movement
- Safe OSK delivery with tissue specificity and cancer surveillance
- Senolytic responder stratification by baseline burden
- Laromestrocel phase 3 and persistence beyond 12 months
- Pig-kidney nanowarming as the next scale test
Resolve next
- Which hallmarks are causal drivers
- Which biological-age measures are stable and predictive
- Whether partial reprogramming preserves cell identity
- Whether plasma effects can be reduced to manufacturable factors
- Whether a connectome is enough to recover a mind
Hold the line
- No human lifespan claim without survival data
- No rejuvenation claim from one biomarker
- No cryonics claim that blurs structure and viability
- No market total without methodology
- No “program” when only adjacent research exists
New aspects to research next
Responder stratification for rapamycin and senolytics; p16-targeted reprogramming delivery; persistent MSC effects and TIE-2; cryoprotectant toxicity in organ banking; and standardized biological-age measurement.
Promote a direction only if the new evidence improves replication, advances from animal to human, reports a prespecified clinical endpoint, or resolves a named safety or delivery constraint.
None. This is the baseline.
The six threads stand as recorded at the founding survey. Later issues report changes against this position, thread by thread, and only where the scan test is met.